Associations of VICTORION-1 PREVENT eligibility with subclinical cardiovascular and inflammatory damage in a European population-based cohort
American Journal of Preventive Cardiology, 2026
Wang N., Bhatt D., Xhaard C., Aggarwal R., Bonaca M., Lesogor A., Dejmek J., Patel M., Stroes E., Taub P., Windecker S., Duarte K., Monzo L., Baudry G., Zannad F., Girerd N.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
CVD | Patient Stratification | Plasma |  Olink Target 96 |
Abstract
Background and aims
The VICTORION-1 PREVENT (V-1P) trial is evaluating the efficacy of inclisiran versus placebo on cardiovascular events in primary prevention patients at high-risk for ASCVD. We assessed whether V-1P eligibility, based on Pooled Cohort Equations (PCE) and Predicting Risk of Cardiovascular Disease Events (PREVENT) equations, was associated with subclinical cardiovascular and inflammatory abnormalities in a healthy European population.
Methods
We included individuals from the STANISLAS cohort in France aged 40–79 years, LDL-C 70–189 mg/dL and without ASCVD or liver disease. Participants were categorized as V-1P eligible using 10-year ASCVD risk using PCE and PREVENT. Associations with vascular, echocardiographic, and biomarkers were assessed using age- and sex-adjusted linear regression.
Results
Among 848 participants (mean age 60 years, 51% female), 16% were eligible per PCE, of which 7% were also eligible with PREVENT. Only one participant was eligible by PREVENT alone. Compared with non-eligible participants, V-1P-eligible individuals, whether by PCE alone or PCE and PREVENT, displayed significant subclinical abnormalities. Compared with V-1P ineligible participants, V-1P eligible participants had increased intima media thickness (+51 µm, p < 0.009 for PCE+PREVENT) and increased mean pulse wave velocity (+0.89 m/s, p < 0.001 for both PCE and PCE+PREVENT) on vascular ultrasound. V-1P eligible participants by PCE+PREVENT also showed signs of subclinical myocardial injury and inflammation, with a 1.3 fold higher troponin (p = 0.015), 1.6-fold higher interleukin-6 (p < 0.001) and a 2-fold higher high sensitivity C-reactive protein (p < 0.001).ConclusionsA large proportion of asymptomatic individuals without known cardiovascular disease would be eligible for the V-1P trial based on both PCE and PREVENT equations. V-1P eligible participants had evidence of subclinical cardiovascular and inflammatory abnormalities.